{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06153758",
            "orgStudyIdInfo": {
                "id": "C3421074"
            },
            "organization": {
                "fullName": "Pfizer",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults",
            "officialTitle": "A Phase 1, Open-Label, Randomized Study With A 5-Period, 4-Sequence, Crossover Design to Compare the Single Dose Pharmacokinetics Between Immediate and Modified Release Formulations of Danuglipron Administered Orally to Healthy Adult Participants",
            "therapeuticArea": [
                "Other"
            ],
            "study": "study-to-learn-how-different-forms-of-the-study-medicine-called-danuglipron-are-taken-up-into-the-blood-in-healthy-adults"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-11-27",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-07-22",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-07-22",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-22",
            "studyFirstSubmitQcDate": "2023-11-22",
            "studyFirstPostDateStruct": {
                "date": "2023-12-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-31",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Pfizer",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of the study is to learn how different forms of a study medication called danuglipron are taken into the blood in healthy adults."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Participants",
                "Healthy Subjects"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Sequence 1",
                    "type": "EXPERIMENTAL",
                    "description": "Period 1: 80 mg dose of danuglipron IR, fasted state (Formulation A, 2\u00d740 mg tablets) Period 2: 80 mg dose of danuglipron MR, fasted state(Formulation B, 1\u00d780 mg tablet) Period 3: 80 mg dose of danuglipron MR, fasted state (Formulation C, 1\u00d780 mg tablet) Period 4: 80 mg of danuglipron MR, fasted state (Formulation D, 1\u00d780 mg tablet) Period 5: 80 mg dose of danuglipron MR, fed conditions (Formulation B, 1\u00d780 mg tablet)",
                    "interventionNames": [
                        "Drug: Formulation A",
                        "Drug: Formulation B",
                        "Drug: Formulation C",
                        "Drug: Formulation D"
                    ]
                },
                {
                    "label": "Sequence 2",
                    "type": "EXPERIMENTAL",
                    "description": "Period 1: 80 mg dose of danuglipron MR, fasted state (Formulation B, 1\u00d780 mg tablet), Period 2: 80 mg tablet of danuglipron MR, fasted state (Formulation D, 1\u00d780 mg tablet), Period 3: 80 mg tablet of danuglipron IR, fasted state (Formulation A, 2\u00d740 mg tablets) Period 4: 80 mg tablet of danuglipron MR, fasted state (Formulation C, 1\u00d780 mg tablet) Period 5: 80 mg dose of danuglipron MR, fed condition (Formulation B, 1\u00d780 mg tablet)",
                    "interventionNames": [
                        "Drug: Formulation A",
                        "Drug: Formulation B",
                        "Drug: Formulation C",
                        "Drug: Formulation D"
                    ]
                },
                {
                    "label": "Sequence 3",
                    "type": "EXPERIMENTAL",
                    "description": "Period 1: 80 mg dose of danuglipron MR, fasted state (Formulation C, 1\u00d780 mg tablet) Period 2: 80 mg dose of danuglipron IR, fasted state (Formulation A, 2\u00d740 mg tablets) Period 3: 80 mg dose of danuglipron MR, fasted state (Formulation D, 1\u00d780 mg tablet) Period 4: 80 mg dose of danuglipron MR, fasted state (Formulation B, 1\u00d780 mg tablet) Period 5: 80 mg dose of danuglipron MR, fed condition (Formulation B, 1\u00d780 mg tablet)",
                    "interventionNames": [
                        "Drug: Formulation A",
                        "Drug: Formulation B",
                        "Drug: Formulation C",
                        "Drug: Formulation D"
                    ]
                },
                {
                    "label": "Sequence 4",
                    "type": "EXPERIMENTAL",
                    "description": "Period 1: 80 mg dose of danuglipron MR, fasted state (Formulation D, 1\u00d780 mg tablet), Period 2: 80 mg dose of danuglipron MR, fasted state (Formulation C, 1\u00d780 mg tablet) Period 3:80 mg dose of danuglipron MR, fasted state (Formulation B, 1\u00d780 mg tablet) Period 4: 80 mg dose of danuglipron IR, fasted state (Formulation A, 2\u00d740 mg tablets) Period 5: 80 mg dose of danuglipron MR, fed consition (Formulation B, 1\u00d780 mg tablet)",
                    "interventionNames": [
                        "Drug: Formulation A",
                        "Drug: Formulation B",
                        "Drug: Formulation C",
                        "Drug: Formulation D"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Formulation A",
                    "description": "Danuglipron IR PF-06882961-82 40 mg Oval White to Off-White Tablet",
                    "armGroupLabels": [
                        "Sequence 1",
                        "Sequence 2",
                        "Sequence 3",
                        "Sequence 4"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Formulation B",
                    "description": "Danuglipron MR, Danuglipron 80 mgA (500 mgW) Oval MR Tablet (Long Release)",
                    "armGroupLabels": [
                        "Sequence 1",
                        "Sequence 2",
                        "Sequence 3",
                        "Sequence 4"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Formulation C",
                    "description": "Danuglipron MR, Danuglipron 80 mgA (1000 mgW) Oval MR Tablet (Long Release)",
                    "armGroupLabels": [
                        "Sequence 1",
                        "Sequence 2",
                        "Sequence 3",
                        "Sequence 4"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Formulation D",
                    "description": "Danuglipron MR Danuglipron 80 mgA (500 mgW) Oval MR Tablet (Short Release)",
                    "armGroupLabels": [
                        "Sequence 1",
                        "Sequence 2",
                        "Sequence 3",
                        "Sequence 4"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Area Under the Plasma Curve from Time Zero to Extrapolated infinite Time (AUCinf) for Formulations A, B, C and D, in a fasted state",
                    "description": "Plasma PF-06882961 PK parameters",
                    "timeFrame": "Day 1 hour (hr) 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and hr 36 and Day 3 hr 48"
                },
                {
                    "measure": "Maximum observed plasma concentration for Formulations A, B, C and D, in a fasted state",
                    "description": "Plasma PF-06882961 PK parameters",
                    "timeFrame": "Day 1 hour (hr) 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and hr 36 and Day 3 hr 48"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of Participants with Non-Serious Adverse Events",
                    "description": "Safety Parameters",
                    "timeFrame": "Baseline to Day 35"
                },
                {
                    "measure": "Number of Participants with Treatment-Emergent Adverse Events",
                    "description": "Safety Parameters",
                    "timeFrame": "Baseline to Day 35"
                },
                {
                    "measure": "Number of Participants with Clinically Significant ECG Abnormalities",
                    "description": "ECG parameters include QTcF, QRS, RR interval, PR interval, and Heart Rate",
                    "timeFrame": "Baseline to Day 35"
                },
                {
                    "measure": "Number of Participants with Clinically Significant Vital Sign Abnormalities",
                    "description": "Vital Signs parameters include diastolic blood pressure, systolic blood pressure, and pulse rate",
                    "timeFrame": "Baseline to Day 35"
                },
                {
                    "measure": "Number of Participants with Clinically Significant Abnormal Laboratory Values",
                    "description": "Blood hematology and Chemistry and Urinalysis",
                    "timeFrame": "Baseline to Day 35"
                },
                {
                    "measure": "Number of Participants with Serious Adverse Events",
                    "description": "Safety Parameters",
                    "timeFrame": "Baseline to Day 35"
                },
                {
                    "measure": "Area Under the Plasma Curve from Time Zero to Extrapolated infinite Time (AUCinf) for MR formulation B in the fed (Test), compared to the fasted state",
                    "description": "Plasma PF-06882961 PK parameters",
                    "timeFrame": "Day 1 hour (hr) 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and hr 36 and Day 3 hr 48"
                },
                {
                    "measure": "Maximum observed plasma concentration for MR formulation B in the fed (Test), compared to the fasted state",
                    "description": "Plasma PF-06882961 PK parameters",
                    "timeFrame": "Day 1 hour (hr) 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and hr 36 and Day 3 hr 48"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years or older and overtly healthy\n* BMI16-32 kg/m2; and a total body weight \\>50 kg (110 lb).\n\nExclusion Criteria:\n\n* Evidence or history of clinically significant medical conditions, any condition possibly affecting drug absorption, any medical or psychiatric conditions\n* Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Pfizer CT.gov Call Center",
                    "role": "CONTACT",
                    "phone": "1-800-718-1021",
                    "email": "ClinicalTrials.gov_Inquiries@pfizer.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Pfizer CT.gov Call Center",
                    "affiliation": "Pfizer",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Anaheim Clinical Trials, LLC",
                    "status": "RECRUITING",
                    "city": "Anaheim",
                    "state": "California",
                    "zip": "92801",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.83529,
                        "lon": -117.9145
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "To obtain contact information for a study center near you, click here.",
                    "url": "https://pmiform.com/clinical-trial-info-request?StudyID=C3421074"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M11901",
                    "name": "Mitoguazone",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}